Medicines losing patent protection

MonthYear

March 2026

5 medicines lost their last listed patent or exclusivity in March 2026.

Mar 1Arnuity Elliptafluticasone furoate · Glaxosmithkline Intellectual Property Development Ltd England
Mar 3Naproxen Sodiumnaproxen sodium · Bionpharma Inc
Mar 7Pradaxadabigatran etexilate mesylate · Boehringer Ingelheim Pharmaceuticals Inc
Mar 7Rextovynaloxone hydrochloride · Amphastar Pharmaceuticals Inc
Mar 11Coreg CRcarvedilol phosphate · Waylis Therapeutics LLC

Dates are the patent and exclusivity end dates listed in the FDA's Orange Book, in its data up to October 9, 2026. Patents can be extended, challenged in court or settled, so a generic may come earlier, later or not at all. This is not legal or medical advice.

About the data·Privacy·Credits